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Abstract
Background: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic
colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based
on patients’ general conditions and comorbidities, treatments’ objectives, and disease characteristics. TRIBE trial
demonstrated a significant advantage in terms of progression-free survival and overall survival for FOLFOXIRI plus
bevacizumab as compared with FOLFIRI plus bevacizumab. Based on recent evidence, the de-intensification of the
upfront regimen after 4–6 months of treatment is nowadays regarded as a valuable option. Moreover, the
prolonged inhibition of angiogenesis, and in particular the continuation of bevacizumab beyond the evidence of
disease progression, is an efficacious strategy in the treatment of metastatic colorectal cancer patients.
Methods/design: TRIBE-2 is a prospective, open-label, multicentric phase III randomized trial in which unresectable
and previously untreated metastatic colorectal cancer patients are randomized to receive first-line FOLFOX plus
bevacizumab followed by FOLFIRI plus bevacizumab after disease progression or FOLFOXIRI plus bevacizumab
followed by the re-introduction of the same regimen after disease progression. The primary endpoint is to compare
the efficacy of the two proposed treatment strategies in terms of Progression Free Survival 2.
Discussion: The TRIBE-2 study aims at answering the question whether the upfront use of FOLFOXIRI improves the
clinical outcome of metastatic colorectal cancer patients, when compared with the pre-planned, sequential use of
oxaliplatin-based and irinotecan-based doublets. Both proposed treatment strategies are designed to exploit the
effectiveness of the prolonged inhibition of angiogenesis, alternating short (up to 4 months) induction periods and
less intensive maintenance phases.
Trial registration: TRIBE2 is registered at Clinicaltrials.gov: NCT02339116. January 12, 2015. TRIBE-2 is registered at
EUDRACT 2014–004436-19, October 10, 2014.
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Background
FOLFOXIRI plus bevacizumab as first-line treatment of
unresectable mCRC
The first-line treatment is a crucial starting point in the
therapeutic route of every metastatic colorectal cancer
(mCRC) patients [1]. The strategic value of this choice
lies in the importance of obtaining disease control, pre-
venting disease progression and achieving symptoms’ re-
lief. Moreover, the first-line treatment allows pursuing
the unique chance of cure for a percentage of patients,
and exploiting subsequent interventions, in terms of
both surgical/locoregional approaches and other sys-
temic treatments. In the last few years, many therapeutic
associations emerged as possible options and the selec-
tion of the most appropriate treatment is a challenging
issue for medical oncologists.
Recent evidences demonstrate that the intensity of
chemotherapy can be modulated: traditional oxaliplatin
or irinotecan-based doublets [2, 3] can be de-potentiated
in fluoropyrimidine monotherapy [4, 5] or intensified in
the triple regimen FOLFOXIRI (5-FU, oxaliplatin and
irinotecan) [6, 7].
In particular, the phase III randomized TRIBE study [6]
strengthened the use of FOLFOXIRI plus bevacizumab
(bev) as a new option for the upfront treatment of mCRC
patients who meet inclusion criteria of the study. This
multicenter trial included 508 patients with unresectable
mCRC to compare FOLFOXIRI plus bev with FOLFIRI
plus bev. Patients received up to 12 cycles of induction
treatment, followed by maintenance therapy with 5-FU/
LV (5-fluorouracil/leucovorin) and bev until disease pro-
gression. The trial met its primary endpoint progression
free survival (PFS). Indeed, the triplet plus bev provided a
significant advantage in terms of PFS as compared with
FOLFIRI (folinic-acid, 5-Fluorouracil, irinotecan) plus bev
(median PFS: 12.1 months versus 9.7 months, HR 0.75,
95% CI 0.62–0.90; P = 0.003). After an extended median
follow-up period of 48.1 months, updated results demon-
strated a significant advantage also in terms of overall sur-
vival (OS) (median OS: 29.8 months versus 25.8 months;
HR 0.80, 95% CI 0.65–0.98; P = 0.030). Subgroup analyses
evidenced no significant interaction between treatment
effect and baseline clinical characteristics or RAS and
BRAF molecular status [8].
Second and further lines of treatment were chosen by in-
vestigators. The 76% of patients in both arms were exposed
to second-line treatments and around 80% of patients in
the experimental arm received again a fluoropyrimi-
dine +/− oxaliplatin +/− irinotecan as part of their
second-line therapy. Of note, while induction treat-
ments were administered up to 6 months, the median
PFS in the FOLFOXIRI plus bev group was longer than
12 months, so that the median duration of oxaliplatin-
and irinotecan-free intervals was around 6 months.
Maintenance therapy after chemotherapy plus
bevacizumab
The optimal duration of chemotherapy and bev is still a
matter of debate [9–11]. Results from recent randomized
studies showed that the de-intensification of the chemo-
therapy backbone while continuing the antiangiogenic is
an efficacious strategy. Maintenance allows to delay pro-
gression, thus prolonging the time interval between the
completion of the induction treatment and the evidence
of disease progression. These longer “full chemother-
apy”-free intervals make more clinically and biologically
sound the reintroduction of agents used during the in-
duction phase after the occurrence of progression.
Three studies compared maintenance strategies follow-
ing chemotherapy plus bev with clinical observation.
SAKK 41/06 [12] was a non-inferiority trial that random-
ized patients that did not progress after 4–6 months of
XELOX (capecitabine/oxaliplatin) or FOLFOX (folinic-
acid, 5-Fluorouracil, oxaliplatin) plus bev, to continue or
not bev alone until disease progression. The non-inferiority
of the observation strategy was not demonstrated in terms
of both time to progression (TTP) and OS.
In the CAIRO-3 trial [13], patients achieving disease
stabilization or response after six cycles of CAPOX (cap-
ecitabine/oxaliplatin) plus bev were randomized between
observation and maintenance treatment with “low dose”
capecitabine plus bev. After the first disease progression,
CAPOX plus bev had to be reintroduced and continued
until the second evidence of disease progression. The
primary endpoint was PFS2, defined as the time from
randomization to progression upon re-introduction of
CAPOX plus bev. Patients in the maintenance arm
achieved a significant benefit in terms of PFS2, PFS and
a non-significant advantage in OS.
Finally, AIO KRK 0207 study [14] investigated whether
treatment discontinuation or continuation with bev alone
was non-inferior to maintenance with fluoropyrimidine/
bev, in mCRC patients who had received 24 weeks of an
oxaliplatin-based doublet. At first progression, re-induction
of the initial treatment was planned. The primary endpoint
was time to failure of strategy (TFS). Results from this trial
showed that bev monotherapy was not inferior to a fluoro-
pyrimidine plus bev as maintenance, while the non-
inferiority was not demonstrated for the observation strat-
egy in terms of TFS. At the time of data analysis, OS results
were extremely immature.
On the basis of these evidences, the opportunity to al-
ternate induction and maintenance phases in the disease
history of mCRC patients is nowadays a valuable option.
Continuation of bevacizumab beyond progression in mCRC
More than 10 years ago, preclinical evidence led to
hypothesize that continuing antiangiogenic treatments
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beyond the occurrence of resistance could be efficacious
in mCRC. Results from the observational studies BRiTE
[15] and ARIES [16] provided initial clinical data sup-
porting this suggestion.
The prospective confirmation of the effectiveness of
the prolonged inhibition of angiogenesis was provided
by the phase III ML18147 [17] and BEBYP trials [18].
ML18147 study [17], conducted in Europe and Saudi
Arabia, randomIzed mCRC patients previously treated
with bev plus a first-line doublet to the switched doublet
with or without bev. Eligible patients were those who
had experienced progressive disease up to 3 months
after discontinuing first-line bev plus chemotherapy. The
use of bev beyond progression provided a significant
advantage in terms of OS, primary endpoint, (11.2 vs
9.8 months, HR: 0.81 [0.69–0.94], p = 0.0062) and PFS
(5.7 vs 4.1 months, HR: 0.68 [0.59–0.78], p < 0.0001).
BEBYP trial [18], contemporaneously conducted in Italy
and prematurely stopped when results from ML18147 were
released, had a similar design. This study evaluated the re-
introduction of bev even in patients who had completed
the first line treatment more than 3 months before disease
progression to first-line. The continuation of bev beyond
progression provided significant benefit in terms of PFS,
primary endpoint, (6.8 vs 5.0 months, HR: 0.72 [0.54–0.97],
p = 0.0029), while no statistically significant differences in
OS (14.1 vs 15.5 months, HR: 0.77 [0.56–1.07], p = 0.12)
were reported. Nevertheless, the trial was clearly underpow-
ered to detect an advantage in terms of survival. The benefit
in PFS in favor of the continuation of bev was observed in
all analyzed subgroups and in particular both in patients
who discontinued bev for more or less than 3 months.
Based on these data, the continuation of bev beyond
progression is an efficacious option in the treatment of
mCRC patients.
Drawing from these evidences the phase III TRIBE-2
study was designed in order to compare two first- and
second-line strategies, aiming at exploiting the effective-
ness of a prolonged inhibition of angiogenesis. A
standard strategy of an upfront doublet (FOLFOX) plus
bev followed by a switched doublet (FOLFIRI) plus bev
after disease progression is compared to a strategy of up-
front FOLFOXIRI plus bev then followed by reintroduc-
tion of FOLFOXIRI plus bev after disease progression.
All combination treatments are repeated up to 8 cycles
and followed by maintenance with a fluoropyrimidine
plus bev, in order to shorten the duration of more inten-
sive treatments and to prolong as more as possible oxali-
platin- and irinotecan-free intervals.
Methods/design
Study treatment
This is a prospective, open-label, multicentric phase III
randomized trial in which initially unresectable and
previously untreated mCRC patients are randomized to
receive two different strategies: first-line FOLFOX plus
bev followed by FOLFIRI plus bev after disease progres-
sion (arm A, standard treatment) or first-line FOLFOX-
IRI plus bev followed by reintroduction of FOLFOXIRI
plus bev after disease progression (arm B, experimental
strategy). All treatments are administrated up to 8 cycles
followed by 5-FU/LV plus bev maintenance until disease
progression, unacceptable adverse events, or consent
withdrawal (Fig. 1).
In the case of surgical radical resection of residual me-
tastases, post-operative therapy with the same pre-
operative regimen is planned up to an overall duration of
6 months (12 cycles), then followed by 5FU/LV plus bev
up to 6 months after resection. This choice lies on the ra-
tionale that, though in the absence of a formal demonstra-
tion, it might be reasonable that if a regimen has allowed
to pursue secondary resection in a specific patient, it will
be also effective in preventing disease relapse (Fig. 2).
Study objectives and endpoints
TRIBE-2 study aims at comparing the efficacy of the two
proposed treatment strategies: the upfront use of the
triplet plus bev followed by the reintroduction of the
Fig. 1 Study treatment
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same regimen at disease progression or the sequential
use of oxaliplatin-based and irinotecan-based doublets,
combined with the antiangiogenic.
The primary endpoint of this trial is Progression Free
Survival 2 (PFS2), beginning with randomization and
ending with the first of the following events: a) death; b)
disease progression on any treatment given after 1st pro-
gression.. Disease status will be evaluated according to
RECIST 1.1 criteria [19]. The determination of disease
progression will be based on investigator-reported mea-
surements and a subsequent central revision is planned.
For patients that will not receive any treatment within
3 months after 1st progression, PFS2 will be equal to
PFS, since in these patients the proposed treatment
strategy has failed; on the other hand, if following a
RECIST but clinically irrelevant disease progression, in-
vestigators decide to wait until the subsequent disease
assessment and the time interval is <3 months, this is
accepted as part of the strategy.
Secondary objectives of this study are to compare the
two proposed treatment strategies in terms of: PFS, 2nd-
PFS,time to failure of strategy, OS, response rate, rate of
secondary R0 resection of metastases, safety profile.
2nd-PFS is defined as the time from the start of the
second-line treatment to the evidence of disease pro-
gression or death from any cause, whichever occurs first.
TFS is defined as the time from randomization to the
first of the following events: death, introduction of a
new drug (a drug that was not included in the original
strategy), evidence of disease progression during treat-
ment with all the drugs of the initial strategy.
Statistical design
Based on the assumption that PFS2 of each arm follows
an exponential distribution and hypothesizing a true HR
for PFS2 of 0.77 between the experimental and the
control group, 466 events are required for a two-sided
unstratified log-rank test to have 80% power with
α = 0.05. Assuming a proportion of PFS2 equal to 50%
at 15 months in arm A, this treatment effect can be
translated to a 9% absolute improvement in PFS2 at
15 months in arm B. With an accrual rate of 200 sub-
jects/year, a minimum follow up period equal to 1.5 years
and an overall dropout rate of 5%, it is required to enroll
654 subjects, randomized in a 1:1 ratio.
A group sequential design with one interim analysis is
planned. The analyses will take place at 2/3 (303 events)
of the events for the primary endpoint, using an O’Brien
Fleming alpha-spending rule. The interim analysis will
assess the superiority of the experimental arm versus the
control group for the primary endpoint: the study will
be considered for early termination only if superiority is
met. The first interim analysis will have a two-sided
alpha level of 0.0131. According to the O’Brien Fleming
spending rule this will leave a two-sided alpha level of
0.0455 for the final analysis. Therefore, the total type I
error rate will be only slightly increased.
Study population
As in previous trials by the GONO group (Table 1) in-
vestigating the use of the triplet, only patients between
18 and 75 years old are eligible. Those between 71 and
75 years old are included only if their ECOG perform-
ance status is 0. Main eligibility criteria include measur-
able disease according to RECIST version 1.1 [19],
adequate bone marrow, liver, and renal function, no pre-
vious exposure to an oxaliplatin-containing adjuvant
therapy. Previous adjuvant chemotherapy with fluoro-
pyrimidines alone is allowed if more than 6 months have
elapsed between the end of the adjuvant therapy and
Fig. 2 Recommended post-operative treatment in the case of radical resection of metastases
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Table 1 TRIBE-2 participating centers
Principal Investigator Site Name City
Sergio Bracarda Ospedale San Donato Arezzo
Angela Buonadonna Centro di Riferimento Oncologico Aviano
Nicola Silvastris IRCCS BARI Bari
Stefania Mosconi A.O. Papa Giovanni XXIII Bergamo
Alberto Zaniboni Fondazione Poliambulanza Istituto Ospedaliero Brescia
Saverio Cinieri Ospedale “SENATORE A. PERRINO” Brindisi
Andrea Mambrini A.S.L. 1 Massa Carrara Carrara
Roberto Bordonaro A.O.R.N.A.S. Garibaldi Catania
Gianluca Tomasello Istituti Ospitalieri di Cremona Cremona
Cristina Granetto Azienda Sanitaria Ospedaliera Santa Croce e Carle Cuneo
Carlo Milandri A.U.S.L. 11 Empoli Empoli
Antonio Frassoldati Azienda Ospedaliero Universitaria di Ferrara Ferrara
Francesco Di Costanzo Azienda Ospedaliero-Universitaria Careggi Firenze
Angela Stefania Ribecco P.O. S. Giovanni di Dio Firenze
Luisa Fioretto Ospedale Santa Maria Annunziata AUSL 10 FI Firenze
Teresa Gamucci Polo Oncologico Provinciale Frosinone Azienda Sanitaria Locale Frosinone
Silvana Chiara IRCCS AOU San Martino Genova
Alberto Sobrero IRCCS Ospedale San Martino IST Genova
Matteo Clavarezza E.O. Ospedali Galliera Genova E.O.G.
Carmelo Bengala A.U.S.L. 9 Grosseto Grosseto
Laura Scaltriti Azienda USL di Reggio Emilia Guastalla
Carlo Aschele Ospedale Felettino ASL 5 Spezzino La Spezia
Gianpiero Romano Ospedale Vito Fazzi Lecce
Antonio Ardizzoia A.O. Provincia di Lecco Lecco
Andrea Bonetti A.U.L.S.S. 21 Legnago Legnago
Samanta Cupini Ospedali Riuniti di Livorno Livorno
Giovanni Luca Frassineti IRCCS-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) Meldola
Filippo De Braud Istituto Nazionale dei Tumori Milano
Mauro Moroni Ospedale San Carlo Borromeo Milano
Luca Gianni Ospedale San Raffaele Milano
Chiara Carlomagno Azienda Ospedaliera Universitaria Federico II Napoli
Sara Lonardi Istituto Oncologico Veneto Padova
Livio Blasi Ospedale “CIVICO - DI CRISTINA - BENFRATELLI” Palermo
Francesca Pucci Azienza Ospedaliera Universitaria Parma
Silvia Brugnatelli Fondazione I.R.C.C.S. Policlinico San Matteo Pavia
Enrichetta Corgna Azienda Ospedaliera di Perugia Perugia
Alfredo Falcone Azienda Ospedaliero Universitaria Pisana Pisa
Giacomo Allegrini Ospedale Felice Lotti Pontedera Pontedera
Samantha Di Donato A.U.S.L. 4 Prato Prato
Maria Banzi Arcispedale Santa Maria Nuova Reggio Emilia
Emiliano Tamburini Ospedale Infermi Rimini
Enrico Cortesi Policlinico Umberto I Roma
Domenico Cristiano Corsi Ospedale San Giovanni Calibita Fatebenefratelli Isola Tiberina Roma
Daniele Santini Policlinico Unversitario Campus Bio-Medico Roma
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disease relapse. Other exclusion criteria include: periph-
eral neuropathy of grade 2 or higher according to NCI-
CTCAE version 4.0 [20] and contraindications to study
drugs.
Study procedures
Patients enrolled in arm A receive up to 8 cycles of m-
FOLFOX6 plus bev, then followed by maintenance with
5FU/LV plus bev at the same dosage used in the last
cycle of m-FOLFOX6 plus bev. In the case of disease
progression they receive up to 8 cycles of FOLFIRI plus
bev, then followed by maintenance with 5FU/LV plus
bev at the same dosage used in the last cycle of FOLFIRI
plus bev. Patients enrolled in arm B receive up to 8 cycles
of FOLFOXIRI plus bev, then followed by maintenance
with 5FU/LV plus bev at the same dosage used in the
last cycle of FOLFOXIRI plus bev. In the case of disease
progression during maintenance, FOLFOXIRI plus bev
will be reintroduced up to 8 cycles, followed by 5FU/LV
plus bev as maintenance. If disease progression occurs
during FOLFOXIRI plus bev a second-line treatment at
investigator’s choice will be administered. Doses of cyto-
toxics adopted in the second-line treatments may be
modified based on adverse events occurred during first-
line. If the planned treatment after progression will be
deemed unfeasible, modified regimens, including dou-
blets plus bev in the triplet arm, are allowed and patients
will be evaluable for the primary endpoint.
Disease assessment is performed every 8 weeks by
means of CT scan.
Safety
The investigator is responsible for ensuring that all adverse
events observed by the investigator or reported by subjects
are properly captured in the subjects’ medical records and
in electronic Case Report Forms (eCRFs). It is left to the
investigator’s clinical judgment to determine whether an
adverse event is related and of sufficient severity to require
the subject’s removal from treatment or from the study.
All serious adverse events (SAEs) occurring during the
study treatment period, defined as through to 6 months
after the last dose of the treatment or the end of the study
whichever is longer, must be reported within 24 h. The in-
vestigator should notify the Sponsor of all SAEs in accord-
ance with local procedures, statutes and the European
Clinical Trial Directive (where applicable). The Sponsor is
responsible for the medical review of all SAEs and for
their notification to the appropriate Ethics Committees,
Competent Authorities and participating Investigators, in
accordance with local requirements and the European
Clinical Trial Directive.
The same procedures are applied to the following ser-
ious and non serious Adverse Events of Special Interest
(AESI) to bev: hypertension ≥ grade 3; proteinuria ≥ grade
3; gastrointestinal perforation, abscesses and fistulae (any
grade); wound healing complications ≥ grade 3; haemor-
rhage ≥ grade 3 (any grade Central Nervous System bleed-
ing; ≥ grade 2 haemoptysis); arterial thromboembolic
events (any grade); venous thromboembolic events ≥
grade 3; posterior reversible encephalopathy syndrome
(any grade); congestive hearth failure ≥ grade 3; non-
gastrointestinal fistula or abscess ≥ grade 2.
Quality
Each participating Investigator is responsible for ensuring
data quality as planned in the Data Validation Plan docu-
ment. Periodic monitoring visits at participating centers
are planned. All information are systematically checked
for consistency, completeness and accuracy by the Coord-
inating Data Center (Clinical Trials Coordinating Center,
Istituto Toscano Tumori), that periodically issues Data
Query Forms in case of inconsistent data. Local quality
control is provided by qualified monitors, responsible for
the consistency of data reported in eCRFs.
Translational analyses
An extensive program of translational analyses is planned.
The availability of tissue specimens (primary tumor or
Table 1 TRIBE-2 participating centers (Continued)
Clementina Savastano OORR S.Giovanni di Dio e Ruggi d’Aragona Salerno
Marco Benasso A.S.L. 2 Savonese Savona
Francesco Di Clemente A.U.S.L. 7 Siena Siena
Alessandro Bertolini Azienda Ospedaliera della Valtellina e della Valchiavenna Sondrio
Patrizia Racca Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino Torino
Massimo Aglietta Istituto di Candiolo IRCCS Torino
Stefania Miraglia AslTO1 Torino
Giuseppe Aprile A.O. Universitaria Santa Maria della Misericordia Udine
Giampaolo Tortora Azienda Ospedaliera Universitaria Integrata Verona
Domenico Amoroso Ospedale Versilia Viareggio
Enzo Maria Ruggeri AUSL Viterbo - Ospedale Belcolle Viterbo
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metastatic site) is mandatory for study entry. Tissue speci-
mens are collected for the central assessment of RAS and
BRAF status and for further molecular analyses. Not only
samples available at baseline, but also those obtained dur-
ing the treatment (i.e. in the case of secondary resections)
are centrally collected. No additional samples, other than
those obtained for clinical purposes, are requested.
Given the growing relevance of techniques able to
monitor the dynamism of tumor evolution across time
and therapies, blood and plasma samples are collected at
baseline, and at the first and second evidence of disease
progression.
Ethics
The protocol is conducted in accordance to the standards
of Good Clinical Practice, in agreement with the principles
laid down by the 18th World Medical Assembly
(Helsinki, 1964) and subsequent amendments (Tokyo
1975, Venice, 1983, Hong Kong, 1989, Somerset West,
1996 and Edinburgh, 2000).
The study (Protocol v.2.1, 2nd September 2014) was
approved in December 2014 by the Ethics Committee of
the Coordinating Center (Comitato Etico Area Vasta
Nord Ovest, CEAVNO) and then approved by the local
Ethics Committees of participating centers. All candidate
patients will provide their informed consent to study
procedures before enrollment in the study.
Discussion
Results from the TRIBE study [6] clearly underlined the
role of FOLFOXIRI plus bev as upfront option for unre-
sectable mCRC patients, confirming the superiority of the
triplet over the doublet FOLFIRI when bev is added to
both regimens. Based on these evidences, the triplet plus
bev is now a widely accepted treatment option, supported
by all major clinical guidelines [21] (http://www.nccn.org/
professionals/physician_gls/pdf/colon.pdf).
The TRIBE-2 study aims at fully answering the ques-
tion of whether the upfront use of FOLFOXIRI improves
the clinical outcome of mCRC patients, when compared
with the pre-planned, sequential use of oxaliplatin-based
and irinotecan-based doublets.
In order to shorten the duration of combination treat-
ments and to exploit the progression delaying ability of
bev-based maintenance, combination regimens are re-
stricted to short induction periods (4 months instead of
6 months previously adopted in the TRIBE study) then
followed by maintenance with fluoropyrimidine plus bev
until tumor progression.
Another phase II study by the GONO group, named
MOMA (NCT02271464), recently evaluated the efficacy
of a 4 months induction treatment with the triplet plus
bev, then followed by maintenance. In this fase II trial,
mCRC patients were randomized to receive up to 8 cycles
of first-line FOLFOXIRI plus bev, followed by bev alone
until disease progression, or the same upfront treatment,
followed by bev plus metronomic capecitabine plus cyclo-
phosphamide [22]. The accrual was completed in March
2015 and results will be available in 2016.
Though acknowledging that a formal demonstration of
PFS2 surrogacy for OS is currently lacking, the choice of
PFS2 as primary endpoint of the TRIBE-2 study reflects
the objective to prospectively compare two strategies,
with pre-planned upfront regimens and treatments after
progression. As specified in the study protocol, PFS2 is
defined as the time from randomization to disease pro-
gression on any treatment given after first progression,
or death, whichever occurs first. While the study will
provide clear evidence about the feasibility and the effi-
cacy of the experimental strategy of reintroduction of
FOLFOXIRI plus bev after progression, the rationale for
considering in the definition of PFS2 “any treatment
given after first progression”, and not only those in-
cluded in the pre-planned treatment strategies, lies in
the objective to pragmatically catch the impact of the
upfront use of FOLFOXIRI plus bev, independently of
the actual re-introduction of the same regimen after
progression.
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